Cerus Corporation
CERSHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCerus Corporation operates as a biomedical products company. Valued at $469.6M, CERS is a small-cap name in its sector. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Market Cap
$469.6M
Beta
1.83
P/E (TTM)
—
P/E (Fwd)
-466.00
EPS (TTM)
$-0.03
EPS (Fwd)
$-0.01
ROE
-10.8%
ROA
-0.5%
Cash
$56.3M
Total Debt
$76.8M
Free CF
$875,250
52W Change
52.3%
Annual Financials
Cash vs Debt
Where CERS stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CERS finished 11.20% below its 150-day moving average ($2.50) and 9.02% below its 200-day moving average ($2.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CERS overbought or oversold?
At the October 20, 2026 close, CERS's RSI(14) was 26.4, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $56.3M in cash, though total debt stands at $76.8M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $875K supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at -10.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $130.9M (2021) to $206.1M (2025), reflecting a 58% increase over the period.
A beta of 1.83 means CERS is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cerus Corporation and its sector.